Monopril (Fosinopril Sodium)

Fosinopril, the active ingredient in Monopril, is an angiotensin‑converting enzyme (ACE) inhibitor presented as an oral dosage form for oral use. It is prescribed to lower high blood pressure and to improve outcomes in patients with heart failure, acting by relaxing blood vessels and reducing fluid retention.

GNH USA supplies Monopril as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides reliable global distribution. Our network ensures timely delivery and regulatory compliance across multiple regions.

Fosinopril is used in the management of cardiovascular conditions that involve the renin‑angiotensin system.

- Hypertension: reduces systolic and diastolic blood pressure, helping to prevent cardiovascular complications. - Heart failure: improves ventricular function and lowers the risk of hospitalization by decreasing afterload and fluid overload. - Post‑myocardial infarction: lowers the chance of subsequent cardiac events by moderating neuro‑hormonal activation.

Fosinopril may cause a range of adverse reactions, from mild to serious.

Common Side Effects: - Cough: persistent dry cough. - Dizziness or light‑headedness, especially after standing. - Headache. - Fatigue or general weakness. - Hypotension: low blood pressure, particularly after the first dose. - Nausea or mild gastrointestinal upset.

Serious or Rare Side Effects: - Angioedema: swelling of the face, lips, tongue, or throat. - Severe hypotension: marked drop in blood pressure leading to fainting. - Acute renal impairment: sudden worsening of kidney function. - Hyperkalemia: elevated potassium levels that may affect heart rhythm. - Neutropenia or agranulocytosis: significant reduction in white blood cells. - Hepatic enzyme elevation: abnormal liver function tests.

Before initiating fosinopril, certain safety considerations should be observed.

- Monitor blood pressure: check regularly after starting therapy and after dose adjustments. - Assess renal function: evaluate serum creatinine and eGFR before treatment and periodically thereafter. - Check electrolytes: especially potassium, to detect hyperkalemia early. - Caution in aortic stenosis: patients may experience marked hypotension. - Avoid concurrent use with aliskiren in diabetic patients: increased risk of renal complications. - Store at ambient temperature: keep below 25°C, protect from moisture and light.

Fosinopril can interact with several medicines; some combinations should be avoided while others require close monitoring.

Major Interactions (Avoid): - Aliskiren in patients with diabetes: heightened risk of renal dysfunction. - Potassium‑sparing diuretics (e.g., spironolactone): may cause dangerous hyperkalemia. - NSAIDs (e.g., ibuprofen, naproxen): can impair renal function and blunt antihypertensive effect. - Lithium: increased lithium levels leading to toxicity. - Other ACE inhibitors or ARBs: additive effects on blood pressure and potassium.

Moderate Interactions (Monitor Closely): - Thiazide diuretics: may enhance hypotensive response. - ARBs (e.g., losartan): combined use may increase risk of renal impairment. - Beta‑blockers: may mask symptoms of hypoglycemia. - Diuretics causing electrolyte shifts: monitor potassium and sodium levels. - Trimethoprim‑sulfamethoxazole: can raise potassium concentrations.